Drug intelligence / Profile preview

SJP-101

Development stage: Preclinical
Lead developer: Sen-Jam Pharmaceutical
Modality: Small Molecules
Administration: Injectable

Overview

SJP-101 is a small molecule therapeutic candidate being developed by Sen-Jam Pharmaceutical for the treatment of arthritis. The drug utilizes a multi-target approach by inhibiting the cyclooxygenase enzymes COX-1 and COX-2 while simultaneously modulating or stabilizing mast cell activity. This dual mechanism is intended to address the inflammatory pathways and cellular mediators involved in arthritic conditions, aiming to reduce both pain and joint inflammation. As of the current pipeline status, SJP-101 is in the discovery phase of development.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on SJP-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJP-101.

Explore the full profile